{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:49:58Z","timestamp":1767649798111},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/qai.0b013e318198a0cc","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T12:39:40Z","timestamp":1242909580000},"page":"390-396","source":"Crossref","is-referenced-by-count":15,"title":["Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients"],"prefix":"10.1097","volume":"50","author":[{"given":"Daniel","family":"Podzamczer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Olmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Boix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Negredo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan A","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Vilades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Hernandez","family":"Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lluis","family":"Force","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Gonzalez","family":"Lahoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pepa","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M","family":"Llibre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mari\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dalmau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esperanza","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Sola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J","family":"Galindo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enric","family":"Pedrol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesus","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier Torre de","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-7-20210131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R2-7-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2007.00426.x","article-title":"Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.","volume":"8","author":"Cooper","year":"2007","journal-title":"HIV Med"},{"key":"R3-7-20210131","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1046\/j.1472-8206.2003.00162.x","article-title":"The pros and cons of noninferiority trials.","volume":"17","author":"Pocock","year":"2003","journal-title":"Fundam Clin Pharmacol"},{"key":"R4-7-20210131","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.37.2.178","article-title":"Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.","volume":"37","author":"Cheeseman","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-7-20210131","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1310\/B5VU-FU5F-QNWC-UDCK","article-title":"Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.","volume":"6","author":"Kappelhoff","year":"2005","journal-title":"HIV Clin Trials"},{"key":"R7-7-20210131","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1097\/00002030-200005260-00001","article-title":"The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.","volume":"14","author":"van Heeswijk","year":"2000","journal-title":"AIDS"},{"key":"R8-7-20210131","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1089\/0889222041524670","article-title":"The relationship between nevirapine plasma concentrations and abnormal liver function tests.","volume":"20","author":"Almond","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R9-7-20210131","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1177\/135965350501000404","article-title":"Are adverse events of nevirapine and efavirenz related to plasma concentrations?","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"R10-7-20210131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135965350501000114","article-title":"Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"R11-7-20210131","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1097\/00002030-200011100-00010","article-title":"Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.","volume":"14","author":"Garcia","year":"2000","journal-title":"AIDS"},{"key":"R12-7-20210131","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/135965350000500405","article-title":"The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.","volume":"5","author":"Raffi","year":"2000","journal-title":"Antivir Ther"},{"key":"R13-7-20210131","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/135965350400900304","article-title":"Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.","volume":"9","author":"Negredo","year":"2004","journal-title":"Antivir Ther"},{"key":"R14-7-20210131","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1021\/tx034064+","article-title":"Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.","volume":"16","author":"Shenton","year":"2003","journal-title":"Chem Res Toxicol"},{"key":"R15-7-20210131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/jac\/dkl534","article-title":"Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.","volume":"59","author":"Maggiolo","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R17-7-20210131","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/QAD.0b013e3282eff388","article-title":"Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.","volume":"21","author":"Parienti","year":"2007","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200904010-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T07:56:17Z","timestamp":1685001377000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200904010-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318198a0cc","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}